BIOMARIN PHARMACEUTICAL INC
BMRNNasdaq
$59.59
↓ -0.7%Jul 17 close · end-of-day
Price
1Y↑ +2.1%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$11.8B
Enterprise Value
$11.0B
P/E
42.9
P/S
3.6
P/B
1.9
EV/EBITDA
28.2
PEG
1.3
FCF Yield
6.5%
Dividend Yield
—
Revenue (TTM)
$3.2B
Net Income (TTM)
$268.7M
Free Cash Flow (TTM)
$767.1M
Gross Margin
—
Operating Margin
9.7%
Net Margin
8.3%
ROE
4.3%
ROIC
4.0%
Debt / Equity
0.2
Net Cash
$792.2M
Return 1Y
+2.1%
Company profile
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease.
- CEO
- Jean-Jacques Bienaimé
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 3,080
- Headquarters
- California
- Website
- biomarin.com
Management & directors
- Hubbard CristinEVP, Chief Commercial Officer
- Friberg Gregory REVP, Chief R&D Officer
- Davis George EricEVP, Chief Legal Officer
- Guyer Charles GregEVP, Chief Technical Officer
- Hardy AlexanderChief Executive Officer
- Mueller BrianEVP, Chief Financial Officer
- Ramchandani Rashmi VirendraVP, Chief Accounting Officer
Roles derived from SEC Form 4 filings.
Earnings
BMRN Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue$766.2M↑ +2.8%
Diluted EPS$0.54↓ -43.2%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | $1.9B | $1.8B | $2.1B | $2.4B | $2.9B | $3.2B |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$43.4M | -$82.3M | $161.0M | $185.8M | $484.2M | $409.5M |
| Net income | $854.0M | -$64.1M | $141.6M | $167.6M | $426.9M | $348.9M |
| Diluted EPS | $4.50 | -$0.35 | $0.75 | $0.87 | $2.21 | $1.80 |
| Operating cash flow | $85.4M | $304.5M | $175.9M | $159.3M | $572.8M | $828.0M |
| Free cash flow | -$28.9M | $209.0M | $54.9M | $62.6M | $487.4M | $725.0M |
| Gross margin | — | — | — | — | — | — |
| Operating margin | -2.3% | -4.5% | 7.7% | 7.7% | 17.0% | 12.7% |
| Net margin | 45.9% | -3.5% | 6.8% | 6.9% | 15.0% | 10.8% |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $712.0M | $745.7M | $747.3M | $745.1M | $825.4M | $776.1M | $874.6M | $766.2M |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | $120.5M | $113.9M | $161.4M | $223.9M | $276.9M | -$46.7M | -$44.6M | $129.6M |
| Net income | $107.2M | $106.1M | $125.0M | $185.7M | $240.5M | -$30.7M | -$46.6M | $105.5M |
| Diluted EPS | $0.55 | $0.55 | $0.65 | $0.95 | $1.23 | -$0.16 | -$0.22 | $0.54 |
| Operating cash flow | $118.8M | $221.5M | $185.6M | $174.4M | $185.3M | $368.7M | $99.6M | $220.7M |
| Free cash flow | $97.4M | $203.0M | $166.1M | $157.6M | $168.2M | $340.2M | $58.9M | $199.7M |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | 16.9% | 15.3% | 21.6% | 30.0% | 33.5% | -6.0% | -5.1% | 16.9% |
| Net margin | 15.1% | 14.2% | 16.7% | 24.9% | 29.1% | -4.0% | -5.3% | 13.8% |
Company news
Jul 13, 2026
- 6d agoBioMarin Pharmaceutical (BMRN) Following Its VOXZOGO FDA Filing And The Case For Undervaluationfinance.yahoo.com
- 7d ago1 of Wall Street’s Favorite Stocks with Competitive Advantages and 2 We Avoidfinance.yahoo.com
- 7d agoU.S. Food and Drug Administration Accepts BioMarin's Supplemental New Drug Application for Full Approval of VOXZOGO® (vosoritide) for Children With Achondroplasiafinance.yahoo.com
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-06-02 | Countouriotis Athena | Award | 7,490 | $0.00 | $0.00 | filing |
| 2026-06-02 | Walbert Timothy P | Award | 7,490 | $0.00 | $0.00 | filing |
| 2026-06-02 | Ho Maykin | Award | 7,490 | $0.00 | $0.00 | filing |
| 2026-06-02 | HOMBACH ROBERT J. | Award | 7,490 | $0.00 | $0.00 | filing |
| 2026-06-02 | Enyedy Mark J | Award | 7,490 | $0.00 | $0.00 | filing |
| 2026-06-02 | Dere Willard H | Award | 7,490 | $0.00 | $0.00 | filing |
| 2026-06-02 | CLARK IAN T | Award | 7,490 | $0.00 | $0.00 | filing |
| 2026-06-02 | Bodem Barbara W. | Award | 7,490 | $0.00 | $0.00 | filing |
| 2026-06-02 | ANDERSON ELIZABETH M | Award | 7,490 | $0.00 | $0.00 | filing |
| 2026-05-20 | Hubbard Cristin· EVP, Chief Commercial Officer | Tax withholding | 2,318 | $50.20 | $116,363.60 | filing |
| 2026-05-07 | Friberg Gregory R· EVP, Chief R&D Officer | Sale | 3,281 | $53.85 | $176,681.85 | filing |
| 2026-03-18 | Davis George Eric· EVP, Chief Legal Officer | Tax withholding | 1,273 | $56.05 | $71,351.65 | filing |
| 2026-03-17 | Hardy Alexander· Chief Executive Officer | Tax withholding | 4,252 | $56.05 | $238,324.60 | filing |
| 2026-03-17 | Mueller Brian· EVP, Chief Financial Officer | Tax withholding | 2,117 | $56.05 | $118,657.85 | filing |
| 2026-03-17 | Guyer Charles Greg· EVP, Chief Technical Officer | Tax withholding | 1,693 | $56.05 | $94,892.65 | filing |
| 2026-03-17 | Friberg Gregory R· EVP, Chief R&D Officer | Tax withholding | 1,629 | $56.05 | $91,305.45 | filing |
| 2026-03-17 | Hubbard Cristin· EVP, Chief Commercial Officer | Tax withholding | 1,245 | $56.05 | $69,782.25 | filing |
| 2026-03-16 | Davis George Eric· EVP, Chief Legal Officer | Tax withholding | 7,177 | $58.51 | $419,926.27 | filing |
| 2026-03-16 | Friberg Gregory R· EVP, Chief R&D Officer | Award | 19,150 | $0.00 | $0.00 | filing |
| 2026-03-16 | Guyer Charles Greg· EVP, Chief Technical Officer | Award | 14,990 | $0.00 | $0.00 | filing |
| 2026-03-16 | Hubbard Cristin· EVP, Chief Commercial Officer | Award | 15,410 | $0.00 | $0.00 | filing |
| 2026-03-16 | Davis George Eric· EVP, Chief Legal Officer | Award | 14,570 | $0.00 | $0.00 | filing |
| 2026-03-16 | Mueller Brian· EVP, Chief Financial Officer | Award | 18,740 | $0.00 | $0.00 | filing |
| 2026-03-16 | Hardy Alexander· Chief Executive Officer | Award | 62,440 | $0.00 | $0.00 | filing |
| 2026-03-13 | Mueller Brian· EVP, Chief Financial Officer | Tax withholding | 9,945 | $58.51 | $581,881.95 | filing |
Showing the latest 25 transactions — full history in the linked SEC filings.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.